Kenneth Peist

This profile gathers the share dealings of Kenneth Peist in Amicus Therapeutics, Inc. Over a trading history stretching from 10 April 2014 to 4 January 2016, the count stands at 18 filings.

Market trades split into 3 purchases (€241k) and 7 sales (€715k). The net balance comes to €474k on the selling side. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 3 share grants and 5 option exercises.

In size, the median ticket on the buying side is €77k.

Most recently, on 6 January 2016, the filings show a share grant in Amicus Therapeutics, Inc. The most recent open-market purchase was published on 25 November 2014, 4,367 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.